Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
作者： Arkadiusz Z. Dudek , Jakub Zolnierek , Anu Dham , Bruce R. Lindgren , Cezary Szczylik
DOI: 10.1002/CNCR.24009
关键词:
摘要: BACKGROUND: Sunitinib and sorafenib are small-molecule tyrosine kinase inhibitors (TKI) with antitumor activity in advanced renal cell carcinoma. A retrospective study was conducted to assess the response of carcinoma sequential treatment these two agents. METHODS: Tumor evaluated by using Response Evaluation Criteria In Solid Tumors (RECIST) criteria patients failing first-line therapy either sunitinib or subsequently receiving second-line other TKI agent. RESULTS: Twenty-nine received followed (Group A), 20 B). drugs were terminated 6 (12%) Group 4 (8%) B because toxicity. Median duration stable disease for Groups 9.5 weeks, respectively. time from starting first progression after second (time progression) 78 37 Multivariate analysis revealed that had a shorter than (risk ratio [RR] 3.0; P = .016). overall survival 102 45 weeks B, respectively (P .061). CONCLUSIONS: The longer control who warrants further investigation. Cancer 2009. © 2008 American Society.
sci-hub.se 参考文章(16)
M. P. Sablin, L. Bouaita, C. Balleyguier, J. Gautier, C. Celier, J. L. Balcaceres, S. Oudard, A. Ravaud, S. Négrier, B. Escudier, Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients Journal of Clinical Oncology. ,vol. 25, pp. 5038- 5038 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.5038
Bernard Escudier, Tim Eisen, Walter M Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Negrier, Christine Chevreau, Ewa Solska, Apurva A Desai, Frédéric Rolland, Tomasz Demkow, Thomas E Hutson, Martin Gore, Scott Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M Bukowski, None, Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 125- 134 ,(2007) , 10.1056/NEJMOA060655
George V Thomas, Chris Tran, Ingo K Mellinghoff, Derek S Welsbie, Emily Chan, Barbara Fueger, Johannes Czernin, Charles L Sawyers, Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nature Medicine. ,vol. 12, pp. 122- 127 ,(2006) , 10.1038/NM1337
Ila Tamaskar, Jorge A Garcia, Paul Elson, Laura Wood, Tarek Mekhail, Robert Dreicer, Brian I Rini, Ronald M Bukowski, None, Antitumor Effects of Sunitinib or Sorafenib in Patients With Metastatic Renal Cell Carcinoma Who Received Prior Antiangiogenic Therapy Journal of Urology. ,vol. 179, pp. 81- 86 ,(2008) , 10.1016/J.JURO.2007.08.127
M. Palma, P. Kokhaei, J. Lundin, A. Choudhury, H. Mellstedt, A. Österborg, The biology and treatment of chronic lymphocytic leukemia. Annals of Oncology. ,vol. 17, ,(2006) , 10.1093/ANNONC/MDL252
David B. Solit, Neal Rosen, Targeting HER2 in prostate cancer: where to next? Journal of Clinical Oncology. ,vol. 25, pp. 241- 243 ,(2007) , 10.1200/JCO.2006.08.8187
Robert J Motzer, Bernard Escudier, Stéphane Oudard, Thomas E Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A Thompson, Robert A Figlin, Norbert Hollaender, Gladys Urbanowitz, William J Berg, Andrea Kay, David Lebwohl, Alain Ravaud, None, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial The Lancet. ,vol. 372, pp. 449- 456 ,(2008) , 10.1016/S0140-6736(08)61039-9
Joshua Ö. Haznedar, Juthamas Sukbuntherng, Katherine G. Moss, Tinya J. Abrams, Julie M. Cherrington, Randall E. Schreck, Jeremy Carver, Cho Tang, Dirk B. Mendel, Gerald McMahon, James G. Christensen, Lesley J. Murray, Leslie B. Lee, Sharianne G. Louie, Emily Chan, Sheri Shirazian, Todd Miller, Guangmin Li, Theresa J. Ngai, Robert A. Blake, A. Douglas Laird, Xiaohua Xin, Li Sun, In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship Clinical Cancer Research. ,vol. 9, pp. 327- 337 ,(2003)
Yusuke Mizukami, Yutaka Kohgo, Daniel C. Chung, Hypoxia Inducible Factor-1–Independent Pathways in Tumor Angiogenesis Clinical Cancer Research. ,vol. 13, pp. 5670- 5674 ,(2007) , 10.1158/1078-0432.CCR-07-0111
Scott M. Wilhelm, Christopher Carter, LiYa Tang, Dean Wilkie, Angela McNabola, Hong Rong, Charles Chen, Xiaomei Zhang, Patrick Vincent, Mark McHugh, Yichen Cao, Jaleel Shujath, Susan Gawlak, Deepa Eveleigh, Bruce Rowley, Li Liu, Lila Adnane, Mark Lynch, Daniel Auclair, Ian Taylor, Rich Gedrich, Andrei Voznesensky, Bernd Riedl, Leonard E. Post, Gideon Bollag, Pamela A. Trail, BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Cancer Research. ,vol. 64, pp. 7099- 7109 ,(2004) , 10.1158/0008-5472.CAN-04-1443